|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...1011121314151617181920...9899» |
- ||| entecavir / Generic mfg.
Trial completion: HBVQuant: Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay (clinicaltrials.gov) - Apr 28, 2016
P=N/A, N=331, Completed, Sponsor: Hologic, Inc.
Recruiting --> Completed
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting (clinicaltrials.gov) - Apr 28, 2016
P2, N=19, Completed, Sponsor: Gilead Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- ledipasvir/sofosbuvir / Generic mfg.
Trial completion, Enrollment change: Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease (clinicaltrials.gov) - Apr 28, 2016
P2, N=10, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=25 --> 10
- Enrollment change, Trial withdrawal, Metastases: A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 27, 2016
P3, N=0, Withdrawn, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed | N=25 --> 10 N=102 --> 0 | Recruiting --> Withdrawn
- ||| MVA-Nsmut HCV vaccine / GSK, AdCh3NSmut HCV vaccine / GSK
Trial completion: Study of a New MVA Vaccine for Hepatitis C Virus (clinicaltrials.gov) - Apr 26, 2016
P1, N=55, Completed, Sponsor: ReiThera Srl
N=102 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed
- entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation (clinicaltrials.gov) - Apr 26, 2016
P4, N=17, Terminated, Sponsor: Taichung Veterans General Hospital
Recruiting --> Completed N=98 --> 17 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Apr 2016; Slow progress in recruiting study patients
- Trial completion, Enrollment change: Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic (clinicaltrials.gov) - Apr 26, 2016
P=N/A, N=653, Completed, Sponsor: St. Michael's Hospital, Toronto
N=98 --> 17 | Recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Apr 2016; Slow progress in recruiting study patients Active, not recruiting --> Completed | N=1000 --> 653
- || Tomudex (raltitrexed) / Pfizer, AstraZeneca
Trial primary completion date: HEARTO: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure (clinicaltrials.gov) - Apr 25, 2016
P2, N=80, Recruiting, Sponsor: Centre Georges Francois Leclerc
Active, not recruiting --> Completed | N=1000 --> 653 Trial primary completion date: Dec 2015 --> Dec 2016
- ||||| Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Enrollment closed, Trial primary completion date: Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Na (clinicaltrials.gov) - Apr 22, 2016
P3, N=453, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Sep 2016
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Trial primary completion date, Metastases: Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Apr 21, 2016
P1, N=70, Active, not recruiting, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Sep 2016 Trial primary completion date: Jun 2015 --> Jun 2016
- Trial primary completion date, IO biomarker: The Pathogenesis of Hepatitis C Virus Vertical Transmission (clinicaltrials.gov) - Apr 21, 2016
P=N/A, N=50, Recruiting, Sponsor: University of North Carolina, Chapel Hill
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Jul 2016 --> Jul 2017
- | ledipasvir/sofosbuvir / Generic mfg.
Trial completion: Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection (clinicaltrials.gov) - Apr 21, 2016
P2, N=40, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Jul 2016 --> Jul 2017 Active, not recruiting --> Completed
- avadomide (CC-122) / BMS
Trial primary completion date, Combination therapy: Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer (clinicaltrials.gov) - Apr 21, 2016
P1, N=40, Recruiting, Sponsor: Celgene Corporation
Active, not recruiting --> Completed Trial primary completion date: Oct 2017 --> Dec 2018
- Hepacid (pegargiminase) / Polaris Pharma
Trial primary completion date: Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 20, 2016
P2, N=40, Recruiting, Sponsor: Polaris Group
Trial primary completion date: Oct 2017 --> Dec 2018 Trial primary completion date: Jun 2016 --> Jul 2017
- | Trial completion, Trial primary completion date: Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation (clinicaltrials.gov) - Apr 20, 2016
P=N/A, N=20, Completed, Sponsor: Seoul St. Mary's Hospital
Trial primary completion date: Jun 2016 --> Jul 2017 Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2015
- alisporivir (DEB-025) / Debiopharm, Solid BioSci
Trial completion, Combination therapy: Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment na (clinicaltrials.gov) - Apr 20, 2016
P2, N=147, Completed, Sponsor: Debiopharm International SA
Recruiting --> Completed | Trial primary completion date: Nov 2015 --> Aug 2015 Active, not recruiting --> Completed
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion, Enrollment change, Trial primary completion date: A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis (clinicaltrials.gov) - Apr 20, 2016
P2, N=5, Completed, Sponsor: Timothy Morgan, MD
Active, not recruiting --> Completed Not yet recruiting --> Completed | N=186 --> 5 | Trial primary completion date: Sep 2018 --> Apr 2016
- | Ximency (daclatasvir/asunaprevir/beclabuvir) / BMS, beclabuvir (BMS-791325) / BMS
Trial completion, Enrollment change, Trial primary completion date: RHACE 1: Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=25, Completed, Sponsor: Timothy Morgan, MD
Not yet recruiting --> Completed | N=186 --> 5 | Trial primary completion date: Sep 2018 --> Apr 2016 Recruiting --> Completed | N=60 --> 25 | Trial primary completion date: Apr 2015 --> Feb 2016
- ||| Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie, Exviera (dasabuvir) / AbbVie
Enrollment closed: CORAL-I: A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients (clinicaltrials.gov) - Apr 18, 2016
P2, N=195, Active, not recruiting, Sponsor: AbbVie
Recruiting --> Completed | N=60 --> 25 | Trial primary completion date: Apr 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: SAKK 77/08: Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer (clinicaltrials.gov) - Apr 15, 2016
P2, N=106, Completed, Sponsor: Swiss Group for Clinical Cancer Research
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Victoza (liraglutide) / Novo Nordisk, Lantus (insulin glargine) / Sanofi, Januvia (sitagliptin) / Merck (MSD)
Trial primary completion date: LIGHT-ON: Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects (clinicaltrials.gov) - Apr 15, 2016
P4, N=150, Recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Oct 2016
- Trial primary completion date: The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease (clinicaltrials.gov) - Apr 15, 2016
P=N/A, N=15, Recruiting, Sponsor: Yale University
Trial primary completion date: Mar 2016 --> Oct 2016 Trial primary completion date: Jan 2017 --> Jan 2018
- Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Trial primary completion date: Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children (clinicaltrials.gov) - Apr 15, 2016
P3, N=10, Recruiting, Sponsor: Kapiolani Medical Center For Women & Children
Trial primary completion date: Jan 2017 --> Jan 2018 Trial primary completion date: Aug 2015 --> Aug 2020
- sorafenib / Generic mfg.
Trial primary completion date, Metastases: Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 14, 2016
P4, N=200, Recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: Aug 2015 --> Aug 2020 Trial primary completion date: Aug 2015 --> Dec 2016
- Trial completion, Trial primary completion date, IO biomarker: Influence of Probiotics on Infections in Cirrhosis (clinicaltrials.gov) - Apr 14, 2016
P=N/A, N=92, Completed, Sponsor: Medical University of Graz
Trial primary completion date: Aug 2015 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Mar 2014
- | Trial completion: Retrovirus Epidemiology Donor Study-II (REDS-II) (clinicaltrials.gov) - Apr 13, 2016
P=N/A, N=0, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Mar 2014 No longer recruiting --> Completed
- L-ornithine-L-aspartate / Generic mfg.
Trial primary completion date: HEAL: L-ornithine L-aspartate in Overt Hepatic Encephalopathy (clinicaltrials.gov) - Apr 12, 2016
P4, N=200, Recruiting, Sponsor: Dayanand Medical College and Hospital
No longer recruiting --> Completed Trial primary completion date: Mar 2016 --> Jun 2016
- Trial completion, Enrollment change, Trial primary completion date, Biopsy: Hepatic Fibrosis Non-invasive Methods Questionnaire (clinicaltrials.gov) - Apr 11, 2016
P=N/A, N=717, Completed, Sponsor: Al-Azhar University
Trial primary completion date: Mar 2016 --> Jun 2016 Recruiting --> Completed | N=4000 --> 717 | Trial primary completion date: Aug 2014 --> Apr 2016
- Trial suspension: Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability (clinicaltrials.gov) - Apr 9, 2016
P2, N=10, Suspended, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | N=4000 --> 717 | Trial primary completion date: Aug 2014 --> Apr 2016 Recruiting --> Suspended
- Phase classification, Enrollment change, Trial termination: The Effect of Probiotics on Non Alcoholic Fatty Liver Disease (clinicaltrials.gov) - Apr 7, 2016
P1, N=38, Terminated, Sponsor: Rabin Medical Center
Phase classification: P=N/A --> P1 | N=120 --> 38 | Not yet recruiting --> Terminated; Time table was unfulfilled due to incompetent research coordinator. Inaccurate results and No conclusions can be withdrawn
- | sorafenib / Generic mfg.
Enrollment closed, Metastases: A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC (clinicaltrials.gov) - Apr 7, 2016
P3, N=338, Active, not recruiting, Sponsor: National Cancer Center, Korea
Inaccurate results and No conclusions can be withdrawn Recruiting --> Active, not recruiting
- Trial primary completion date: Genetics of Fatty Liver Disease in Children (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=1000, Recruiting, Sponsor: Yale University
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Dec 2020
- Trial primary completion date: Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC (clinicaltrials.gov) - Apr 7, 2016
P3, N=668, Recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: Dec 2015 --> Dec 2020 Trial primary completion date: Aug 2017 --> Aug 2016
- | ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed, Trial primary completion date: HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection (clinicaltrials.gov) - Apr 7, 2016
P2, N=20, Active, not recruiting, Sponsor: HepNet Study House, German Liverfoundation
Trial primary completion date: Aug 2017 --> Aug 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Aug 2016
- ||| Pegasys (pegylated interferon α -2a) / Roche
Trial completion: An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=959, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Aug 2016 Active, not recruiting --> Completed
- alisporivir (DEB-025) / Debiopharm, Solid BioSci
Enrollment change, Trial termination, Combination therapy: Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1 (clinicaltrials.gov) - Apr 7, 2016
P3, N=8, Terminated, Sponsor: Debiopharm International SA
Active, not recruiting --> Completed N=210 --> 8 | Completed --> Terminated
- Trial primary completion date: AEMD-IDE-20: Safety Study of the Aethlon Hemopurifier (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=10, Recruiting, Sponsor: Aethlon Medical Inc.
N=210 --> 8 | Completed --> Terminated Trial primary completion date: Oct 2015 --> Dec 2016
- || Pegasys (pegylated interferon ? -2a) / Roche
Trial primary completion date: An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study (clinicaltrials.gov) - Apr 7, 2016
P=N/A, N=70, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Oct 2015 --> Dec 2016 Trial primary completion date: May 2016 --> Jun 2018
- ||||| Exviera (dasabuvir) / AbbVie
Enrollment closed: Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease (clinicaltrials.gov) - Apr 7, 2016
P3, N=70, Active, not recruiting, Sponsor: AbbVie
Trial primary completion date: May 2016 --> Jun 2018 Recruiting --> Active, not recruiting
- || Xalkori (crizotinib) / Pfizer
Enrollment closed, Metastases: Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients (clinicaltrials.gov) - Apr 7, 2016
P1, N=70, Active, not recruiting, Sponsor: Pfizer
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- alisporivir (DEB-025) / Debiopharm, Solid BioSci
Trial completion, Combination therapy: ALtitude II: Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option (clinicaltrials.gov) - Apr 7, 2016
P2, N=52, Completed, Sponsor: Debiopharm International SA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Engerix-B (hepatitis B vaccine recombinant) / GSK
Enrollment closed, Combination therapy: Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System (clinicaltrials.gov) - Apr 4, 2016
P2, N=90, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Trial completion: A Trial of Complete Versus Selective HepaticVascular Clamping in Hepatectomy (clinicaltrials.gov) - Apr 2, 2016
P=N/A, N=320, Completed, Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Trial completion: TACEPVE: Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC (clinicaltrials.gov) - Apr 2, 2016
P=N/A, N=20, Completed, Sponsor: Eastern Hepatobiliary Surgery Hospital
Active, not recruiting --> Completed Recruiting --> Completed
- Licartin (Iodine-131-labeled metuximab) / Chinese Government
Trial completion: Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 2, 2016
P4, N=400, Completed, Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- | Fraxiparine (nadroparin) / Aspen
Trial completion, Trial primary completion date: The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 2, 2016
P2/3, N=100, Completed, Sponsor: Eastern Hepatobiliary Surgery Hospital
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2009 --> Aug 2011
- Trial completion, Phase classification: Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion (clinicaltrials.gov) - Apr 2, 2016
P1/2, N=352, Completed, Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting --> Completed | Trial primary completion date: Dec 2009 --> Aug 2011 Active, not recruiting --> Completed | Phase classification: P1 --> P1/2
- Trial completion: A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 2, 2016
P=N/A, N=160, Completed, Sponsor: Eastern Hepatobiliary Surgery Hospital
Active, not recruiting --> Completed | Phase classification: P1 --> P1/2 Recruiting --> Completed
- | Trial completion: SHVE: Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy (clinicaltrials.gov) - Apr 2, 2016
P2/3, N=132, Completed, Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting --> Completed Recruiting --> Completed
- | Trial completion: Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels (clinicaltrials.gov) - Apr 2, 2016
P2/3, N=120, Completed, Sponsor: Eastern Hepatobiliary Surgery Hospital
Recruiting --> Completed Recruiting --> Completed